Plains Venture PartnersPlains Venture PartnersPlains Venture PartnersPlains Venture Partners
  • About
  • Portfolio
  • Team
  • Investor Login

i2E helps OMRF as commercialization partner

    Home News i2E helps OMRF as commercialization partner
    NextPrevious

    i2E helps OMRF as commercialization partner

    By sarah | News | 0 comment | 6 February, 2019 | 0

    By Scott Meacham
    Copyright © 2019, The Tulsa World/BH Media Group

    The Oklahoma Medical Research Foundation is one of the finest biomedical research institutions in the world. I2E is honored to be a commercialization partner with this organization of 400-plus scientists who evince such a passion and singular focus on understanding and curing human disease.

    What does it mean to be OMRF’s commercialization partner? Our job is to step in and step up to add our capital, connections and expertise to OMRF’s remarkable science.

    We work together to create companies that move valuable medical technologies from bench to bedside — devices, diagnostics, and therapies — to better help patients and generate great returns.

    There is nothing prescribed or cookie-cutter about commercializing scientific discovery, other than it takes years to discover the science and then prove its efficacy and safety in treating human disease.

    Therefore, on promising discoveries, we and OMRF approach opportunities with a flexible mindset to figure out just what it will take — in science and investment capital — to build a business and cure a disease.

    A recent example of that is our joint venture to develop a novel therapeutic to treat glioblastoma, a deadly form of brain cancer — the cancer that took the life of U.S. Sen. John McCain last year. There is currently no cure for glioblastoma; the standard treatment is surgery followed by radiation and chemotherapy, but the deadly tumor almost always grows back.

    OMRF developed an investigational drug called OKN-007 that has been in clinical testing at the University of Oklahoma’s Stephenson Cancer Center. OKN-007, which was long-supported by research funding from the Oklahoma Center for the Commercialization of Science and Technology, also received funding from i2E’s Oklahoma Seed Capital Fund.

    In October, Oblato Inc., U.S.-based subsidiary of a Korea investment firm that focuses on rare disease indications, purchased all rights to OKN-007. Oblato will initiate additional trials in larger populations and has plans to develop an oral form of the drug, which is now administered as an infusion.

    This project is noteworthy as, to my knowledge, it is the first of its kind in Oklahoma where a not-for-profit research institution without clinical infrastructure collaborates under a novel investment model to manage a new drug therapy through clinical trials, delivering results that generate a commercial collaboration.

    “It is a testament to the collaborative spirit of the people and institutions of this state,” said Manu S. Nair, OMRF’s vice president for Technology Ventures. “The seamless collaboration of several institutions made it logistically possible as if it was all done within and by one entity.”

    What collaborating on a project like this means to Oklahoma is significant. With OMRF, we have a remarkable source of research and innovation in bioscience. In OCAST we have an established model of research funding (one that we should invest in more if we really want to grow research in Oklahoma).

    And with i2E’s capital and venture model, we can invest human resources and money early enough to make enough progress to attract significant outside investment into Oklahoma’s bioscience deals.

    What that means to the rest of the world is that possibly, someday there will be a cure for glioblastoma and other devastating diseases.

    Scott Meacham is president of i2E Inc., which receives state support from the Oklahoma Center for the Advancement of Science and Technology. Contact him at i2E_Comments@i2E.org.

    Read the article at the Tulsa World website

    glioblastoma, Oklahoma Medical Research Foundation, Scott Meacham

    Related Post

    • Norman’s IMMY has global impact, despite humble beginnings

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019 The Oklahoman Sean and Scott Bauman, CEO and chief operating officer of biotechnology company IMMY, literally grew up in the family business. “There isn’t a job that my brotherRead more

    • Oklahoma’s bioscience prowess busy making a difference worldwide

      By sarah | 0 comment

      By Kevan Goff-ParkerCopyright © 2019 The Oklahoman Greater Oklahoma City Chamber Manager of Innovation and Entrepreneurship Evan Fay said he believes some people may be caught off-guard by Oklahoma’s growing bioscience prowess. He made hisRead more

    • Ascend BioVentures helps determine right path for health care discoveries

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019, The Oklahoman It’s really difficult to invent new drug therapies. Research and development can take decades. Once a potential drug appears viable, testing for safety and efficacy adds moreRead more

    • OSU delegates share future bioscience innovations with leaders

      By sarah | 0 comment

      By Kevan Goff-Parker Copyright © 2019, The Oklahoman PHILADELPHIA — Three Oklahoma State University researchers this week have been connecting face-to-face with some of the world’s top bioscience companies during the 2019 BIO International ConventionRead more

    • Delegation Sharing Oklahoma’s Good News Bioscience Story at BIO International Convention

      By sarah | 0 comment

      By Kevan Goff-Parker Copyright ©2019, The Oklahoman PHILADELPHIA — More than 40 Oklahoma bioscience and industry experts from a wide array of fields are busy telling global industry leaders about the state’s successes in theRead more

    Leave a Comment

    Cancel reply

    You must be logged in to post a comment.

    NextPrevious

    Investor Login

    • Disclaimer & Disclosure

    Oklahoma City Location

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305

    Click HERE for directions.

    Tulsa Location

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592

    Click HERE for directions.

    • Disclaimer & Disclosure
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • About
    • Portfolio
    • Team
    • Funds
    • Investor Login
    Plains Venture Partners